Abstract
The pathological aggregation of tau into paired helical filaments is a hallmark of several neurodegenerative diseases, including Alzheimers disease. We have generated cell models of tau aggregation in order to study mechanisms involving abnormal changes of tau. In the cell models the repeat domain of tau (tauRD) and some of its variants are expressed in a regulated fashion, e.g. the 4-repeat domain of tau with the wild-type sequence, the repeat domain with the ΔK280 mutation (“pro-aggregation mutant”), or the repeat domain with additional proline mutations (“anti-aggregation mutant”). The aggregation of tauRD is toxic to the cells, but aggregation and toxicity can be prevented by low molecular weight compounds identified by a screen for inhibitors. Thus the cell models are suitable for developing aggregation inhibitor drugs and testing their cellular roles.
Keywords: Alzheimer's disease, paired helical filaments, tau, drug screening
Current Alzheimer Research
Title: Inhibition of Tau Aggregation in Cell Models of Tauopathy
Volume: 4 Issue: 5
Author(s): Inna Khlistunova, Marcus Pickhardt, Jacek Biernat, Yipeng Wang, Eva-Maria Mandelkow and Eckhard Mandelkow
Affiliation:
Keywords: Alzheimer's disease, paired helical filaments, tau, drug screening
Abstract: The pathological aggregation of tau into paired helical filaments is a hallmark of several neurodegenerative diseases, including Alzheimers disease. We have generated cell models of tau aggregation in order to study mechanisms involving abnormal changes of tau. In the cell models the repeat domain of tau (tauRD) and some of its variants are expressed in a regulated fashion, e.g. the 4-repeat domain of tau with the wild-type sequence, the repeat domain with the ΔK280 mutation (“pro-aggregation mutant”), or the repeat domain with additional proline mutations (“anti-aggregation mutant”). The aggregation of tauRD is toxic to the cells, but aggregation and toxicity can be prevented by low molecular weight compounds identified by a screen for inhibitors. Thus the cell models are suitable for developing aggregation inhibitor drugs and testing their cellular roles.
Export Options
About this article
Cite this article as:
Khlistunova Inna, Pickhardt Marcus, Biernat Jacek, Wang Yipeng, Mandelkow Eva-Maria and Mandelkow Eckhard, Inhibition of Tau Aggregation in Cell Models of Tauopathy, Current Alzheimer Research 2007; 4 (5) . https://dx.doi.org/10.2174/156720507783018307
DOI https://dx.doi.org/10.2174/156720507783018307 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patients Stratification Strategies to Optimize the Effectiveness of Scavenging Biogenic Aldehydes: Towards a Neuroprotective Approach for Parkinson's Disease
Current Neuropharmacology Molecular Mechanisms of Action of Gas1 and its Possible Therapeutic Applications
Current Signal Transduction Therapy Neuroprotective Properties of Erythropoietin in Cerebral Ischemia
Central Nervous System Agents in Medicinal Chemistry Neuroprotective Gene Therapy for Parkinson’s Disease
Current Gene Therapy Diversity and Variability of the Effects of Nicotine on Different Cortical Regions of the Brain. Therapeutic and Toxicological Implications
Central Nervous System Agents in Medicinal Chemistry A General Method for the Synthesis of 11H-Indeno[1,2-B]Quinoxalin- 11-Ones and 6H-Indeno[1,2-B]Pyrido[3,2-E]Pyrazin-6-One Derivatives Using Mandelic Acid as an Efficient Organo-catalyst at Room Temperature
Current Organocatalysis Targeting the Pleiotrophin/Receptor Protein Tyrosine Phosphatase β /ζ Signaling Pathway to Limit Neurotoxicity Induced by Drug Abuse
Mini-Reviews in Medicinal Chemistry The ALK Gene, An Attractive Target for Inhibitor Development
Current Topics in Medicinal Chemistry Dynamical Behaviors of the Transcriptional Network Including REST and miR-21 in Embryonic Stem Cells
Current Bioinformatics Role of Complement Systems in IVIG Mediated Attenuation of Cognitive Deterioration in Alzheimer's Disease
Current Alzheimer Research Antiproliferative Activity of microRNA-125a and its Molecular Targets
MicroRNA Sigma Receptors in Oncology: Therapeutic and Diagnostic Applications of Sigma Ligands
Current Pharmaceutical Design New Insights into Serotonin 5-HT4 Receptors : A Novel Therapeutic Target for Alzheimers Disease?
Current Alzheimer Research Studies on Anticancer Activities of Lactoferrin and Lactoferricin
Current Protein & Peptide Science Xanthohumol: A Metabolite with Promising Anti-Neoplastic Potential
Anti-Cancer Agents in Medicinal Chemistry Pluripotent Stem Cell-Derived Somatic Stem Cells as Tool to Study the Role of MicroRNAs in Early Human Neural Development
Current Molecular Medicine Membrane Targeted Chemotherapy with Hybrid Liposomes for Tumor Cells Leading to Apoptosis
Current Pharmaceutical Design Recent Advances in Biological Tissue Imaging with Time-of-Flight Secondary Ion Mass Spectrometry: Polyatomic Ion Sources, Sample Preparation, and Applications
Current Pharmaceutical Design MicroRNAs: Key Players in Microglia and Astrocyte Mediated Inflammation in CNS Pathologies
Current Medicinal Chemistry Infective Proteins: The Prion Puzzle
Current Protein & Peptide Science